Partner with us

We’re committed to building sustainable relationships across the scientific and business communities that help us combine transformative advances in the understanding of human disease with the science of therapeutics, all with the goal of advancing human health.

Female scientist speaks with business partner

We’re committed to building sustainable relationships across the scientific and business communities that help us combine transformative advances in the understanding of human disease with the science of therapeutics, all with the goal of advancing human health.

Collaboration defines our culture

We know that collaborating with the world’s experts is a cornerstone to solving some of science’s most difficult problems. Collaboration is one of our core values at Vertex — it defines our culture.

two female business partners in a meeting


Externally, our collaborations with companies, academia, research organizations and nonprofit organizations help drive scientific innovation and the development of new medicines.

two female business partners in a meeting


Internally, it creates an environment that encourages the open exchange of ideas and provides the freedom for our talented employees to explore new scientific concepts. Our Vertex Opportunities for Intrapreneurship & Corporate Evolution (VOICE) program is a great example. Check it out here.

Partnerships enhance scientific innovation

To support our mission, we seek external partnerships that promote scientific innovation, and we’re focused on creating relationships that are grounded in deep biological knowledge of a disease and target. We believe that innovation should not be limited to opportunities based solely on specific stages of development or on particular treatment modalities.

 

Scientific equipment inside fume hood
Our current priorities include:
  • Supporting Vertex’s cystic fibrosis strategy of bringing innovative medicines to patients by complementing our existing research efforts and clinical assets with additional tools and/or technologies. 

  • Diversifying our portfolio with potentially transformative medicines in diseases where there is a high unmet need. 

  • Leveraging cutting-edge technology platforms to accelerate the discovery of new disease targets, compounds, delivery mechanisms and potential treatment modalities. 

  • Maximizing the potential of Vertex assets by using strategic collaborations and licensing opportunities to enable speedy and thorough development. 

Vertex is a trusted partner

Female businesswoman speaking in meeting

We value developing strategic relationships that are mutually beneficial. Our approach is to create successful partnerships with well-articulated principles and value propositions. Our portfolio of alliances consists of a variety of collaboration models to meet the different needs of our partners. 

Vertex works to maximize the value of our partnerships for both organizations, seeking to make decisions that align our common goals and, most importantly, bring benefits to patients as quickly as possible. We work collaboratively to make informed and strategic decisions to rapidly progress our partnered programs.

Areas of interest

We're actively exploring all approaches that may change the treatment of a serious disease where no adequate treatment currently exists. We are seeking technologies that will enable exploration of new diseases or disease targets.

Please also contact us if you'd like to explore a potential partnership related to any of the following:

White background

Our global network of innovation

Targets and Human Cell Models
Genomics plc logo

Genomics plc

August 30, 2018 announcement

Innovation in Small Molecule Therapeutics
X-Chem Pharmaceuticals logo

X-Chem

January 4, 2019 announcement

Kymera logo

Kymera

May 15, 2019 announcement

Ribometrix logo

Ribometrix

September 30, 2019 announcement

Skyhawk Therapeutics logo

Skyhawk Therapeutics

December 22, 2020 announcement

Stablix logo

Stablix

April 25, 2023 announcement

Cell and Genetic Therapies
CRISPR Therapeutics logo

CRISPR Therapeutics

April 20, 2021 announcement

Moderna logo

Moderna

September 16, 2020 announcement

July 6, 2016 announcement

 

Affinia Therapeutics logo

Affinia Therapeutics

April 27, 2020 announcement

Arbor logo

Arbor Biotechnologies

January 3, 2019 announcement

Mammoth Biosciences logo

Mammoth Biosciences

October 26, 2021 announcement

Obsidian Therapeutics logo

Obsidian Therapeutics

April 22, 2021 announcement

Verve Therapeutics logo

Verve Therapeutics

July 20, 2022 announcement

Entrada Therapeutics logo

Entrada Therapeutics

December 8, 2022 announcement

Tevard Biosciences logo

Tevard Biosciences

February 28, 2023 announcement

ImmunoGen logo

ImmunoGen

March 1, 2023 announcement

Lonza logo

Lonza

June 26, 2023 announcement